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Background: Peripheral arterial disease (PAD) is associated with increased cardiovascular 
mortality that correlates with peripheral perfusion impairment as assessed by the ankle-brachial 
arterial pressure index (ABI). PAD leads to arterial stiffness and increased pulse wave velocity that 
might impact central aortic pressures and subendocardial perfusion during diastole. 
Aim: To investigate whether ABI impairment correlates with the aortic augmentation index (AIx), 
a measure of pulse wave velocity and reflection, and the subendocardial viability ratio (SEVR). 
Patients and Methods: AIx and SEVR were assessed by radial applanation tonometry in 65 
patients with stable PAD (Rutherford stage I-III) at a tertiary referral center. Alx (corrected for 
heart rate) and SEVR were tested in univariate and multivariate linear regression models to 
determine the association with ABI. 
Results: Mean values were ABI 0.8 ± 0.2, AIx 31 ± 7%, and SEVR 141 ± 26%. Multiple linear 
regression with AIx as the dependent variable revealed a significant negative association with ABI 
(β = -11.5 [95% confidence interval (CI), -18.6 to -4.5], p = 0.002). Other variables associated with 
AIx included diastolic blood pressure (β = 0.2 [95% CI, 0.1 to 0.4], p < 0.001), height (β = -46.2 
[95% CI, -62.9 to -29.4], p < 0.001), body mass index (β = -0.4 [95% CI, -0.8 to -0.1], p = 0.023), and 
smoking (β = 3.6 [95% CI, 0.6 to 6.6], p = 0.019). Multiple regression with SEVR as the dependent 
variable showed a significant correlation with ABI (β =33.2 [95% CI, 2.3 to 64.1], p = 0.036).  
Conclusion: Severity of lower limb perfusion impairment is related to central aortic pressure 
augmentation and to SEVR. This may be a pathophysiologic mechanism that impacts cardiac 





Peripheral arterial disease (PAD) is a common manifestation of atherosclerosis affecting more 
than 5% of the aged population 1-2. Despite having a relatively low rate of peripheral 
complications and limb amputations, PAD is associated with impairment in functional activity and 
an increased risk of cardiovascular events 3-4. For this reason, PAD is considered a marker for 
systemic atherosclerosis 5. To date, the most powerful prognostic indicator in PAD patients is the 
ankle-brachial pressure index (ABI) 6-8. ABI is used to measure impairment of lower limb perfusion 
and has been shown to predict survival rate in patients with PAD 1, 9-10. 
The mechanisms through which the presence of PAD increases the risk of cardiovascular events 
are not understood in detail. PAD represents a vascular disease with extensive atherosclerotic 
involvement. This is paralleled by systemic inflammation and increased level of oxidative stress, 
both are known to destabilize atherosclerotic plaque and may thus be associated with vascular 
events 11. In addition, the extensive atherosclerotic alterations along the vascular tree conduit are 
thought to increase pulse wave velocity and lower limb arterial obstructions may favor premature 
pulse wave reflections 12-13.  
Pulse wave analysis conducted using radial tonometry has been shown to correlate with both 
invasively measured central aortic pressure and subendocardial perfusion, and has been applied 
to investigate arterial stiffness in different diseases 14.   
Khalegi et al have reported that pathological ABI was independently associated with increased 
central aortic pressure augmentation12. Whether the degree of ABI impairment is linked to 
elevated central aortic pressures and decreased subendocardial viability ratio (SEVR) is not known 
to date. 
We hypothesize that the degree of ABI impairment is related to increased central aortic 
augmentation index (AIx) and decreased SEVR and therefore assessed these surrogate markers 






This prospective, single-centre evaluation assessing ABI and pulse wave analysis in consecutive 
patients with PAD was conducted at a tertiary referral centre. Only patients with chronic and 
stable PAD were eligible for the study. Exclusion criteria were critical limb ischemia (Rutherford 
IV-VI), cardiac arrhythmia, and chronic inflammatory vascular disorders. Patients with 
incompressible tibial and peroneal arteries due to mediacalcinosis were excluded. Patients were 
not withdrawn from regular medication. The local ethics committee approved the study (Nr. 
1741/2009) and all patients provided written informed consent. The study was conducted 
according to Good Clinical Practice standards. The following data were collected: medical history, 
peripheral systolic and diastolic blood pressures, body mass index, vascular risk factors (arterial 
hypertension, diabetes mellitus, dyslipidemia, smoking), comorbidities and medication, ABI, and 
pulse wave analysis. 
 
Ankle-brachial arterial pressure index assessment 
ABI assessment was performed as part of the standard diagnostic procedure. Brachial systolic and 
diastolic blood pressures on both arms with traditional cuff manometry were measured in 
triplicate according to the Riva Rocci method. Systolic ankle blood pressures of the posterior tibial 
artery, anterior tibial artery, and peroneal artery on both legs were obtained by hand-held 6 MHz 
Doppler probe (Kranzbühler, Logidop 2, Pilger Medical Electronics, Switzerland). For both legs, ABI 
was calculated as the ratio of the highest ankle pressure divided by the highest brachial systolic 
blood pressure. The lower ABI value was chosen as study parameter, because of its higher 
correlation with PAD severity. 
 
Radial artery pulse wave analysis  
Applanation tonometry of the radial artery was performed with the SphygmoCor system (AtCor 
Medical, Sydney, Australia) by a single observer, with patients in the supine position to acquire 
radial artery waveforms 15. A validated transfer function was used to generate the corresponding 
ascending aortic pressure waveform. Augmented pressure was defined as the difference between 
the second and the first systolic peak, and AIx was expressed as a percentage of the pulse 
pressure (difference between systolic and diastolic pressure) 16.  AIx was corrected for heart rate 
of 75 per minute (AIx@HR75). Subendocardial blood supply as a parameter evaluating the risk of 
myocardial ischemia was expressed with the SEVR, the ratio of the diastolic phase (diastolic time 








Descriptive statistics for continuous variables are given as mean ± standard deviation. For 
categorical variables, results are presented as a frequency and a percentage. ABI was considered 
as an independent variable, and AIx and SEVR as dependent variables. We examined univariate 
and multivariate linear regression models to determine the association between ABI and the 
augmentation index (AIx@HR75) and SEVR. The following covariates were used in the multivariate 
models: age, sex, systolic and diastolic blood pressure, height, body mass index, cardiovascular 
risk factors (hypertension, smoking history, diabetes mellitus, and dyslipidemia), comorbidities 
(coronary artery disease, cerebrovascular disease, renal insufficiency), and use of antihypertensive 
medication. All continuous variables were centered at their respective means. Categorical 
variables were dichotomized as present or absent. Comorbidities were dichotomized and marked 
as present in subjects with either prevalent cardiovascular or cerebrovascular disease, or renal 
insufficiency. Similarly, medication was dichotomized and categorized as present in case a subject 
was under current treatment with an angiotensin converting enzyme-inhibitor, an angiotensin-II-
receptor inhibitor, a calcium-antagonist, or nitrates. We included interaction terms between all 
covariates in the model and the ABI. Interaction was graphically inspected in addition to a chunk-
wise statistical assessment using the multiple-partial F-test to compare the unrestricted and 
restricted model. Next, a chunk-wise elimination of non-significant main effects was performed. 
Robustness of the modelling strategy was verified by using other modelling strategies (stepwise 
backward and forward procedures). Values of 2-sided p < 0.05 were considered statistically 
significant.  All analyses were performed with Stata 11.1 for Windows (StataCorp LP, College 





The characteristics of the study population are summarized in table 1.  
Graphical as well as statistical examination did not indicate any relevant interaction between the 
candidate covariates and the two independent variables of interest (p = 0.186 for the model 
assessing AIx@HR75, and p = 0.576 for the model assessing SEVR). 
Data on ABI, heart rate, and pressure characteristics, as well values for AIx and SEVR, are provided 
in table 2.  
When using a univariate linear regression, AIx was significantly associated with ABI with a 
coefficient of -13.0 (95% confidence interval [CI], -21.6 to -4.4; p = 0.004). All covariates except 
diastolic blood pressure, history of smoking, height, and body mass index were removed from the 
model in backward multiple linear regression elimination with AIx@HR75 as the dependent 
variable (table 3). The multiple-partial F-test between the unrestricted model and the final model 
indicated a significance of 0.351. Total variance of AIx@HR75 explained by the final model was 
51%. The selection of variables included into the model was confirmed by the stepwise selection 
procedures. The partial regression plot for AIx@HR75 and ABI are shown in figure 1 and indicated 
that the lower the ABI, the higher AIx@HR75. 
Likewise, univariate linear regression revealed a statistically significant association between SEVR 
and ABI, with a coefficient of 54.0 (95% CI, 22.0 to 86.0; p = 0.001). In the multiple linear 
regression model, the β for the ABI was 33 (95% CI, 2.3 – 64.1; p = 0.036). Significance from the 
multiple-partial F-test between the unrestricted model and the final model was 0.657. The model 
indicated a 0.35 variance of SVER. The partial regression plot for SEVR and ABI are shown in figure 
2 and exhibited a positive correlation between ABI and SEVR. Stepwise procedures again 















The main finding of this study is that the severity of PAD—as assessed by ankle-brachial arterial 
pressure index—is independently associated with central aortic pressure augmentation and SEVR. 
This indicates that the impairment of peripheral arterial perfusion has a negative effect on systolic 
and diastolic cardiac function. Although epidemiological studies have shown that ABI is a powerful 
prognostic parameter for survival in PAD patients, the distinct pathophysiologic mechanism is still 
not fully understood 1, 17.   
Only limited data exist on AIx in patients with peripheral arterial disease 12-13, 18. By examining 457 
adults without history of coronary artery or cerebrovascular disease, Khalegi et al reported that 
AIx@HR75 is independently associated with a pathological ABI 12. In our study we have 
additionally demonstrated that the severity of lower limb arterial perfusion inversely correlates 
with AIx@HR75. Khalegi et al used the ABI as the variable of interest (dependent) and reported an 
association with AIx@HR75, older age, shorter height, female sex, and anti-hypertensive 
medication. In our model using AIx as the variable of interest and investigating only subjects with 
PAD, we found a significant association with ABI, height, body mass index, smoking, and diastolic 
blood pressure. Similarly, Amoh-Tonto et al reported that patients with coronary artery disease 
and ABI below 0.94 had higher AIx than those with normal ABI.  
In addition to the evaluation of central aortic pressure augmentation, pulse wave analysis allows 
for the assessment of SEVR 19-20. The ratio of the diastolic (diastolic time index) to the systolic 
phase (time tension index) in the central aortic profile has a close correlation with the blood 
supply to the subendocardium 20-21. Hence, SVER derived from aortic pulse waveforms is a non-
invasive estimation of subendocardial blood supply. Saito et al found that AIx and pulse pressure 
(systolic-diastolic pressure amplitude) are independent predictors for lower coronary flow reserve 
22. In our study, the model of multivariate regression analysis with SEVR as the dependent variable 
shows that there is a significant association between ABI and systolic and diastolic peripheral 
blood pressures. In addition to the inverse correlation between ABI and AIx, our findings suggest 
that PAD is associated with elevated central aortic pressure and decreased subendocardial blood 
supply, which indicates that the degree of peripheral perfusion impairment may affect 
subendocardial perfusion.  
In order to understand this potential pathophysiologic context in PAD, the physiology of pulse 
wave propagation and reflection need to be reviewed. PAD impairs arterial compliance due to 
atherosclerotic arterial wall changes, resulting in increased arterial wall stiffness along the 
vascular conduit with a poorer distal run-off. This is thought to lead to a central systolic pressure 
augmentation and decreased central diastolic pressure through a) increased pulse wave velocity, 
given that pulse wave propagation is accelerated by elevated arterial stiffness, and b) premature 
pulse wave reflections at atherosclerotic bifurcations and obstructions 23-25. The extent of arterial 
stiffness and the number and pattern of arteries and arterioles of the distal run-off are important 
determinants of the timing and amplitude of the arterial wave reflection 26. Premature arterial 
wave reflection impacts on cardiovascular risk because elevated AIx has been reported to be 
associated with coronary artery disease and cardiovascular events 27-29. These hemodynamic 




(central systolic pressure augmentation) and may decrease myocardial perfusion due to a lower 
pressure during diastole 22. Buckberg et al have demonstrated that the ratio of the area of the 
diastolic phase (diastolic pressure time index) to that of the systolic phase (time tension index) in 
the central aortic profile has a close correlation with the blood supply to the subendocardium 30-
31.  
Elevated AIx and lower SEVR may cause acceleration of coronary artery disease and render 
atherosclerotic plaque more vulnerable due to a possibly impaired coronary blood flow during 
diastole 22. Further studies on this pathophysiologic mechanism are needed to prove these 
findings. The assessment of AIx and SEVR can thus be considered easily accessible surrogate 
parameters of cardiovascular risk and might be used to study the effect of different treatment 
options as well as lifestyle modification in patients with PAD. It nevertheless remains uncertain 
whether the assessment of AIx and SEVR provides more powerful information concerning the 
cardiovascular prognosis of these high-risk patients than the measurement of ABI. Moreover, the 
present analysis is based on a cross-sectional study design investigating a small population with 
PAD. Therefore, other factors that might contribute to the correlation between ABI and 
cardiovascular prognosis are eventually not identified, since multilevel vascular involvement, 
inflammation, and decreased physical activity are potential cofactors influencing the prognosis. A 
reduction in physical activity has been shown to correlate with increased cardiovascular 
morbidity. Interestingly, two independent groups have recently reported that pulse wave velocity 
is associated with walking distance even after adjustment for ABI in patients with PAD (n=75 and 
n= 106) 13, 32.  
In conclusion, AIx and SEVR are related to ankle-brachial arterial pressure index in patients with 
PAD independent of age, comorbidity, and medication. This indicates a strong association 
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Table 1. Characteristics of the study population (n=65) 
  
Age (years) 69 ± 11 
Female, n (%) 17 (26) 
Body height (cm) 170 ± 7.9 
Weight (kg)  74.5 ± 12.6 
Body mass index (kg/m2) 25.7 ± 3.7 
Cardiovascular risk factors, n (%)  
 Hypertension  52 (80) 
 History of smoking 48 (74) 
 Diabetes  15 (23) 
 Dyslipidemia  39 (60) 
Comorbidities, n (%)  
 Coronary artery disease  19 (29) 
 Cerebrovascular disease  15 (23) 
 Renal insufficiency  8 (12) 
Medication, n (%)  
 Nitrates 2 (3) 
 ß-blockers 35 (54) 
 ACE inhibitors 28 (43) 
 Angiotensin receptor blockers 16 (25) 
 Calcium channel blockers 19 (29) 
 Diuretics 30 (46) 
 Lipid-lowering medication 54 (83) 
   
Table entries are mean ± SD for quantitative variables and numbers 





Table 2. Pressure characteristics of patients (n=65) 
   
ABI 0.8 ± 0.2 ( 0.4 - 1.2) 
AIx@75HR 31 ± 7 (17 - 47) 
SEVR 141 ± 26 (90-230) 
Heart rate (bpm) 67 ± 9 (48 - 89) 
SBP (mmHg) 152 ± 21 (120 - 250) 
DBP (mmHg) 81 ± 11 (60 - 110) 
Brachial PP (mmHg) 71 ± 18 (40 - 150) 
Central PP (mmHg) 59 ± 17 (29-135) 
   
Table entries are mean ± SD (range). Bpm, beats per minute ; SBP, systolic 






Table 3. Variables associated with aortic augmentation index in patients with peripheral arterial disease 
 Unrestricted Model Restricted Model 
 Coef. 95% CI p Coef. 95% CI p 
ABI -10.67 -18.36 -2.97 0.008 -11.5 -18.6 -4.5 0.002 
Age, years 0.06 0.10 0.23 0.449     
Sex 0.17 -3.66 4.00 0.929     
Height, cm -42.27 -63.38 -21.16 <0.001 -46.2 -62.93 -29.43 <0.001 
Body mass index, kg/m2 -0.45 -0.87 -0.024 0.039 -0.43 -0.80 -0.06 0.02 
Smoker 5.20 1.54 8.86 0.006 3.6 0.60 6.59 0.02 
Dyslipidaemia 0.25 -2.64 3.14 0.862     
Hypertension 0.56 -3.98 5.09 0.806     
Diabetes 0.10 -3.56 3.77 0.955     
Systolic blood pressure 0.02 -0.07 0.11 0.680     
Diastolic blood pressure 0.23 0.06 0.40 0.009 0.24 0.12 0.36 <0.001 
Comorbidities -0.99 -4.24 2.27 0.546     




Table 4. Variables associated with subendocardial viability ratio in patients with peripheral arterial disease 
 Unrestricted Model Restricted Model 
 Coef. 95% CI p Coef. 95% CI p 
ABI 37.29 4.12 70.45 0.028 33.17 2.29 64.06 0.04 
Age, years 0.02 -0.69 0.73 0.952     
Sex -17.05 -33.55 -0.54 0.043 -14.96 -30.06 0.14 ns 
Height, cm 96.55 5.59 187.52 0.038 76.76 -6.67 160.18 ns  
Body mass index, kg/m2 0.36 -1.47 2.18 0.696     
Smoker 1.35 -14.4 17.12 0.864     
Dyslipidaemia -1.08 -13.54 11.39 0.863     
Hypertension 14.07 -5.48 33.61 0.155     
Diabetes -8.07 -23.85 7.72 0.310     
Systolic blood pressure -0.72 -1.12 -0.32 0.001 -0.61 -0.96 -0.25 0.001 
Diastolic blood pressure 0.99 0.26 1.71 0.009 0.80 0.17 1.43 0.01 
Comorbidities 7.44 -6.58 21.46 0.292     
Antihypertensive drugs 0.24 -16.46 16.93 0.978     
17 
 
Figure 1. Partial regression plot for aortic augmentation index and ankle-brachial pressure 









Figure 2. Partial regression plot for subendocardial viability ratio and ankle-brachial pressure 
index in patients with peripheral arterial disease 
19 
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